UAE Obesity Statistics 2026: Burden, Policy Response & the GLP-1 Market Landscape

What Is the Most Useful Obesity Figure for the UAE?

The most defensible answer is that there is no single UAE obesity number; there are different numbers for different jobs. WHO’s age-standardized national estimate is the right reference if the goal is cross-country comparison. The Dubai Academic Health Corporation paper is more useful if the goal is to understand the burden showing up in a large real-world urban health-system sample. The two should not be treated as contradictory. They measure different populations and different summary frames.

The Dubai study is especially important because it is the largest obesity prevalence dataset yet published from the region, covering 440,590 adults attending public-sector sites between 2018 and 2023. It found that 63.4% were living with overweight or obesity and 28.0% with obesity. UAE nationals had a heavier burden than other population groups in the dataset, reaching 68.3% living with overweight or obesity. For searchers asking why UAE obesity figures look different across websites, this is usually the answer: some pages cite a national obesity-only estimate, while others cite a Dubai overweight-plus-obesity sample.

That distinction makes this page different from our UAE GLP-1 access and pricing guide. Here, the job is not to tell readers what a prescription product costs. It is to explain why the UAE has become such an important metabolic-disease market in the first place, which starts with reading the burden data correctly.

How Large Is the Linked Diabetes Burden?

The obesity conversation becomes much more consequential once it is paired with the UAE diabetes profile. The IDF Diabetes Atlas 11th edition estimates that 1.274 million adults in the UAE were living with diabetes in 2024, and that the age-standardized prevalence was 20.7%. That is why the UAE repeatedly appears in global metabolic-disease discussions even when country-level obesity estimates vary by method.

One of the most important details in the IDF profile is not prevalence alone but detection. The Atlas estimates that 64.0% of diabetes cases in the UAE are undiagnosed. That matters for market interpretation: a large metabolic burden does not automatically mean neat, fully identified treatment pathways. It means health systems, screening programs, primary care, and pharmacy demand can all move at different speeds.

For GLP-1 research, that combination of high excess-weight burden, high diabetes prevalence, and large undiagnosed share is the real story. It creates a market where demand is not being driven by one variable such as aesthetics or trend usage alone. The category sits on top of a broader metabolic screening and chronic-disease problem.

What Is the Official UAE Policy Response?

The official stance has become clearer in the last year. In March 2025, MoHAP described obesity as a strategic priority for the UAE health system. In the same update, the ministry pointed to collaboration with WHO, school-health and childhood-obesity initiatives, training on obesity indicators, and work on a national scientific guide for obesity management and weight control.

MoHAP also said the upcoming National Health and Nutrition Survey would measure obesity rates among adults and children across the country. That matters because it signals a move from broad awareness messaging toward more standardized national measurement. For researchers and analysts, that is one of the strongest clues that obesity in the UAE is now being treated as an infrastructure question, not just a lifestyle topic.

World Obesity Federation arrives at the same issue from a different angle. Its 2024 UAE briefing warns that the economic impact of obesity is on track to approach 5% of GDP by 2035. That estimate is not a prevalence figure, but it is a useful reminder that the UAE obesity story is already an economic and system-capacity story, not only an individual-risk story.

How Should Readers Interpret the UAE GLP-1 Landscape?

The right interpretation is that UAE GLP-1 demand is being built by epidemiology first and product competition second. Obesity and diabetes prevalence create the underlying demand pool; policy attention, screening efforts, and clinician adoption determine how fast that demand becomes visible in prescribing and pharmacy channels. This is why the UAE matters in the broader incretin conversation even when brand-level pricing or availability changes month to month.

That is also why we keep this page separate from our brand-by-brand UAE GLP-1 availability and cost guide. If you need prescription access rules, approximate pharmacy pricing, or brand comparisons, use that page. If you need the why now behind the UAE metabolic market, this is the better starting point.

May 2026 Landscape Updates

UAE EDE Foundayo Approval — Late April 2026 (Second Country Worldwide)

The UAE Emirates Drug Establishment (EDE) approved Foundayo (orforglipron) in early April 2026, making the UAE the second country in the world to approve the first oral non-peptide GLP-1 receptor agonist for chronic weight management. First supplies became available in May 2026. EDE Director-General Dr. Fatima Al Kaabi described the approval as a milestone. The FDA had approved Foundayo on April 1, 2026. Unlike Rybelsus or other oral peptide formulations, it has no food or water restrictions. For mechanism, dosing, and trial data, see the Foundayo orforglipron profile. Sources: gulfnews.com; khaleejtimes.com.

Novo Nordisk + UAE EDE: Global Pharmaceutical Distribution Hub (May 22, 2026)

Novo Nordisk and the UAE EDE announced on May 22, 2026 that the UAE would serve as one of three global pharmaceutical distribution hubs worldwide, supporting approximately 70 countries and 2.6 million patients. This is a supply-chain and trust signal: distribution infrastructure for incretin medicines is being built in partnership with the UAE federal regulator. Sources: gulfnews.com; healthcaremea.com; khaleejtimes.com.

Retatrutide TRIUMPH-1 Readout — May 21, 2026

Retatrutide’s pivotal TRIUMPH-1 obesity readout was reported on May 21, 2026 and is relevant input for landscape forecasting in this region. Retatrutide remains investigational and is not an approved UAE medicine; nothing here suggests otherwise. The reason it earns a place in a UAE obesity-landscape page is forward-looking: triple-agonist Phase 3 data anchors where the obesity pharmacology ceiling is heading, and that ceiling moves how analysts size the regional category over the next several years. UAE regulatory pathways for retatrutide are not yet announced and we do not speculate on them. See the retatrutide in Dubai research guide for full research-use context.

Incretin Market Scale — Lilly & Novo Q1 2026

Global incretin demand helps frame UAE projections. Lilly Q1 2026 (April 30, 2026): Mounjaro WW revenue $8.66B (+125% YoY); Zepbound $4.2B (+80%); total Lilly $19.8B (+56%). Novo Nordisk Q1 2026 (May 6, 2026): total DKK 96.8B (+32% CER); obesity care +22% CER; Wegovy pill first launch quarter DKK 2.26B. Cited as global market-size context. Sources: investor.lilly.com; novonordisk.com.

UAE 2031 Obesity Macro Report — Government Priority Signal

A May 2026 report by the UAE Ministry of Economy, Whiteshield, and Eli Lilly modeled accelerated intervention outcomes: 1.2M+ adults could exit obesity by 2031, delivering a ~15-percentage-point prevalence decline, +$51B in GDP, and $1.5B in healthcare savings. This is a forward-looking economic model, co-authored by the UAE government, signaling that obesity has moved firmly into the national economic-development agenda. Sources: aletihad.ae; healthcaremea.com; emirates247.com.

Where Does Retatrutide Fit in This Landscape?

Retatrutide belongs in the research and pipeline layer, not the approved-prescription layer. It is a next-generation triple-agonist candidate often discussed alongside semaglutide, tirzepatide, and CagriSema when analysts map where obesity pharmacology may be heading. On this site, it is covered strictly in research-use terms and should not be presented as an approved UAE treatment product.

If you want a deeper research-only breakdown, use our retatrutide in Dubai guide. If you want a mechanism and pipeline comparison, use our retatrutide vs tirzepatide vs CagriSema analysis. For approval timing across the wider category, use the obesity drug approval tracker.